MedTrace Logo

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

NCT00542425 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2017-10-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether BA058 is effective in building bone in postmenopausal women with osteoporosis.

Conditions

Interventions

DRUG

teriparatide

teriparatide 20 µg subcutaneous daily

DRUG

Placebo

Placebo subcutaneous daily

DRUG

BA058 20 µg

BA058 20 µg subcutaneous daily

DRUG

BA058 40 µg

BA058 40 µg subcutaneous daily

DRUG

BA058 80 µg

BA058 80 µg subcutaneous daily

Sponsors & Collaborators

  • Radius Health, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Radius Health, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00542425 on ClinicalTrials.gov